Study #2024-1300
A confirmatory phase 3 multicenter, randomized, double-blind, placebo-controlled study of the efficacy of topical HyBryte (hypericin sodium) and visible-light activation for the treatment of cutaneous T-cell lymphoma (CTCL)
MD Anderson Study Status
Enrolling
Treatment Agent
Hypericin, Placebo
Description
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
Study phase:
Phase III
Physician name:
Auris Huen
Department:
Dermatology
For general questions about clinical trials:
1-844-285-5619
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.